This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Dermatitis Safety Treatments 
Dermatology Times
APRIL 12, 2024
Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives. She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment.
85 
Dermatology Times
SEPTEMBER 26, 2023
Ruth Ann Vleugels, MD, and Christopher Bunick, MD, agreed that the long-term safety data for JAK inhibitors makes them preferable to systemic steroids.
87 
Dermatology Times
JUNE 10, 2024
Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.
73 
Dermatology Times
OCTOBER 11, 2023
The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.
81 
The Dermatology Digest
APRIL 7, 2024
A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Nonsteroidal treatment options for AD have rapidly expanded in recent years with the development of phosphodiesterase-4 inhibitors, biologics, and Janus kinase (JAK) inhibitors.
77 
Dermatology Times
JANUARY 2, 2025
The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.
36 
Dermatology Times
MAY 13, 2024
They are confident prescribing roflumilast to patients with diverse skin and hair characteristics, including those with a history of hair treatments.
74 
The Dermatology Digest
JANUARY 29, 2024
Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. It is the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades. in seborrheic dermatitis. in seborrheic dermatitis.
74 
The Dermatology Digest
DECEMBER 13, 2024
Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.
69 
Dermatology Times
MAY 6, 2024
Elizabeth Kiracofe, MD, provides a look at an upcoming DermView program that will explore systemic treatments for atopic dermatitis in the context of reproductive health, for patients during pregnancy, pre-pregnancy, postpartum, and breastfeeding.
36 
The Dermatology Digest
FEBRUARY 14, 2024
Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.
78 
The Dermatology Digest
JANUARY 14, 2024
People with seborrheic dermatitis who don’t use topical steroids are 3.5 Zoryve foam is a once-daily steroid-free topical for use in all skin and hair types that effectively clears and controls seborrheic dermatitis. Food and Drug Administration (FDA) approved topical roflumilast foam (Zoryve, Arcutis) for seborrheic dermatitis.
72 
The Dermatology Digest
FEBRUARY 14, 2024
VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. and is the same strength and formulation studied in the ADORING Phase 3 development program and included in the sNDA submission for atopic dermatitis.
74 
Dermatology Times
OCTOBER 3, 2023
Experts in dermatology discuss their considerations for atopic dermatitis and plaque psoriasis topical treatment options highlighting the different penetration, access, and safety considerations.
36 
Dermatology Times
JUNE 12, 2024
Experts on atopic dermatitis discuss the importance of open dialogue with patients who are pregnant or of childbearing potential regarding the safety concerns associated with treatments for this condition.
36 
The Dermatology Digest
SEPTEMBER 26, 2024
Food and Drug Administration approved for prurigo nodularis (PN), nemolizumab (Nemluvio, Galderma) improved signs and symptoms of atopic dermatitis for more than one year, according to the ARCADIA open-label extension study. The safety profile was consistent with that previously reported, the study showed. Safety is not an issue.
74 
Dermatology Times
DECEMBER 24, 2024
A panelist discusses how the current treatment options for atopic dermatitis range from topical corticosteroids and calcineurin inhibitors for mild cases to systemic medications such as dupilumab and Janus kinase inhibitors for moderate-to-severe disease, with selection based on factors such as disease severity, patient age, and safety considerations. (..)
36 
Alison Bladh
JANUARY 1, 2025
Lets dive into the causes of thinning brows and explore effective treatments that can help restore their shape, fullness, and confidence. Skin Conditions Conditions like eczema, psoriasis, or seborrheic dermatitis can irritate the skin around the brows, leading to hair loss. Why Do Eyebrows Thin as We Age?
52 
Dermatology Times
JUNE 2, 2024
James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.
52 
The Dermatology Digest
JANUARY 20, 2024
By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases, including chronic spontaneous urticaria and inflammatory itch. Evommune, Inc.
74 
Dermatology Times
JUNE 19, 2024
Dermatologists provide clinical insights on how they discuss atopic dermatitis treatment options, considerations, and safety concerns with patients who are pregnant or of childbearing age.
36 
Dermatology Times
JULY 8, 2024
Robert Bruce Posnick, MD, examines a case of a 55-year-old female patient with a 50-year history of atopic dermatitis, comorbid asthma, and severe alopecia areata, presenting with recurrent patches throughout her body, predominantly affecting her face, hands, trunk, arms, legs, and eyelids.
36 
The Dermatology Digest
FEBRUARY 8, 2024
Psoriasis is also undergoing a revolution with the development of new oral treatments that act like injectable biologics, and this is of interest to patients who do not want a shot,” he says. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.”
78 
Dermatology Times
AUGUST 24, 2023
Experts discuss the results of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).
36 
Dermatology Times
AUGUST 16, 2023
Christopher Bunick, MD, PhD, introduces the objectives and design of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).
36 
Dermatology Times
AUGUST 9, 2023
Christopher Bunick, MD, PhD, discusses the major study conclusions about the safety of upadacitinib as a treatment for atopic dermatitis.
36 
Dermatology Times
JULY 10, 2024
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, have a comprehensive discussion on treatment safety considerations for patients with atopic dermatitis who are breastfeeding.
36 
The Dermatology Digest
DECEMBER 15, 2023
The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.
36 
First Derm
FEBRUARY 21, 2024
Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.
80 
The Dermatology Digest
MAY 16, 2024
million, five-year National Institutes of Health (NIH) U01 grant to investigate dupilumab (Dupixent, Sanofi & Regeneron) as a treatment for children with alopecia areata. Current treatment options for alopecia areata harbor negative side effects for long-term use. Dr. Guttman. “If
69 
The Dermatology Digest
DECEMBER 15, 2023
They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.
36 
First Derm
AUGUST 25, 2023
However, it is important to address the misconception that “natural” automatically equates to safety. By addressing the misconception surrounding the safety of natural skin care products, we can better understand the need for careful evaluation and consideration when choosing these products.
40 
Dermatology Times
JANUARY 13, 2025
A panelist discusses how health care providers can address patients concerns about topical treatment side effects in atopic dermatitis by providing education about proper application, expected outcomes, and the strong safety profile of modern topical medications.
36 
The Dermatology Digest
JANUARY 10, 2025
is initiating a Phase 2b dose-ranging trial for its CGB-500 (1% tofacitinib), a topical Janus kinase (JAK) inhibitor ointment for moderate to severe atopic dermatitis (AD) and low body surface area (BSA) involvement. CAGE Bio, Inc. CGB-500 was developed using CAGE Bio’s proprietary ionic liquid technology.
36 
The Dermatology Digest
OCTOBER 26, 2024
Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. Both groups had similar proportions of patients with treatment-emergent adverse events (TEAEs).
36 
The Dermatology Digest
JANUARY 16, 2024
and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. “It is important to have systemic treatments approved for CHE, both with and without atopic dermatitis. . and Sanofi report. “We
36 
The Dermatology Digest
JANUARY 13, 2025
Nektar Therapeutics has completed target enrollment in its REZOLVE-AD Phase2bstudy of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (AD). Proof-of-concept efficacy and safety data from a Phase1bstudy of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress.
36 
The Dermatology Digest
APRIL 30, 2024
Eli Lilly has resubmitted its Biologics License Application (BLA) for Lebrikizumab for the treatment of moderate to severe atopic dermatitis (AD), with regulatory action anticipated in the second half of 2024. There were no concerns with lebrikizumab’s clinical data package, safety, or label.
36 
The Dermatology Digest
JANUARY 11, 2024
of atopic dermatitis (AD) patients using Vtama (tapinarof) cream, 1% achieved Eczema Area and Severity Index (EASI )75 in an integrated analysis of all the ADORING Program studies, Dermavant reports. Vtama cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. Fully 80.7%
36 
The Dermatology Digest
JANUARY 23, 2024
Nemolizumab improves skin lesions, itch, and sleep disturbance in patients with moderate-to-severe atopic dermatitis (AD), according to results from two phase 3 studies. Galderma’s nemolizumab is a first-in-class interleukin-31 receptor alpha antagonist that is under investigation for atopic dermatitis.
36 
The Dermatology Digest
MARCH 11, 2024
In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks. No new safety signals were observed in this trial.
36 
The Dermatology Digest
JULY 19, 2024
Limiting the use of oral corticosteroid treatment to 90 days or less may limit adverse effects in patients with atopic dermatitis (AD). This is the main takeaway from a new nested case-control study in JAMA Network Open that looked at the long-term use of oral corticosteroids and safety outcomes for AD patients.
36 
US Dermatologt Partners
SEPTEMBER 23, 2024
It’s important to develop healthy skin habits to slow the signs of aging around the eyes, and there are also dermatologic treatment options available when you need to hit the reset button.” Chronic skin conditions – poorly managed chronic skin conditions like eczema and dermatitis may damage or dilate blood vessels around the eyes.
41 
The Dermatology Digest
JULY 10, 2024
for use in moderate to severe atopic dermatitis (AD) in the NHS England. The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy.
36
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content